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ABSTRACT 
The use of dipeptidyl peptidase-IV (DPP-IV) inhibitors has been an established practice in the management of type-2 diabetes 
mellitus in recent years. The present study undertakes De-novo design protocol for the exploration of some new lead compounds 
which can further be optimized for their development as DPP-IV inhibitors. The e-lea3d drug design pipeline was used to “grow” the 
molecules inside the active site of DPP-IV and molecular docking results were used for the filtration of compounds with important 
binding interactions. 
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INTRODUCTION: 
Diabetes mellitus (DM) has two major subtypes: Type-1 
(T1DM) and Type 2 (T2DM). T1DM essentially results 
from inhibition of insulin secretion whereas a resistance 
to insulin is the characteristic of T2DM. Initially in 
T2DM, the enhanced synthesis and secretion of insulin 
by pancreas makes up for the resistance but, over time 
this ability decreases to keep up the blood glucose at 
normal levels. Amongst various reasons for insulin 
resistance, one is the very short half life of the incretin 
hormones glucagon like peptide (GLP) and gastric 
inhibitory peptide (GIP)
1
. These hormones improve the 
function and efficiency of pancreatic β cells leading to 
an indirect positive effect on insulin release. The 
truncation of GLP through hydrolysis by DPP-IV 
renders this enzyme a striking target for T2DM therapy. 
Furthermore in recent past there have been many DPP-
IV inhibitors launched throughout the world, sitagliptin, 
vildagliptin, alogliptin and saxagliptin to name a few
1
. 
In continuation to the above efforts, new scaffolds can 
be explored for development of new DPP-IV inhibitors. 
Thus the present study employs de-novo design strategy 
for identification of new leads capable of DPP-IV 
inhibition. De-novo design is one of the essential tools 
in drug discovery process in modern age. As an iterative 
process using three-dimensional structure of the receptor 
to design newer molecules, it involves structure 
determination of the lead target complexes and 
designing of improved leads using molecular modeling 
tools. Design of new chemical classes of compounds 
that present similar substituents to the target using a 
template or scaffold, which is chemically distinct from 
previously characterized leads is one of the 
distinguishing features of this method
2
.  
MATERIALS AND METHODS: 
The e-lea3d drug design pipeline
2
 was used for 
generating and rearrangement of fragments to generate 
new molecular structures. It uses PLANTS (Protein 
Ligand ANT System)
3
 as the docking tool for docking 
and scoring of the newly generated structures. The 
crystal structure of DPP-IV bound to sitagliptin (PDB 
ID: 1X70) was retrieved from protein data bank
4
. The 
structure was prepared through addition of hydrogens 
and minimizing through YASARA web server
5
. The 
water molecules were removed from the minimized 
structure and the protein molecule was loaded to the 
pipeline. The active site coordinates were defined as X: 
40.000, Y: 52.000, Z: 35.785 and the radius was defined 
as 10 Å.  
RESULTS AND DISCUSSION 
The present study encompasses exploration of new 
scaffolds as DPP-IV inhibitors through de-novo design 
approach. The program PLANTS was used for docking 
and scoring the structures generated through 
rearrangement of fragments of FDA approved drugs. 
Through iterative runs, different conformations of ~250 
structures were docked and scored. Among these, some 
of the compounds with their binding scores and 
interactions are reported hereunder: 
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 Table 1: Some of the Top scoring compounds retrieved from de-novo design strategy 
S. No. Compound structure Binding score Polar interactions 
1 
 
-106.313 GLU 205 
2 
 
-105.23 
GLU 206, VAL 207, 
ARG 358, TYR 547, 
TYR 662, ASN 710 
3 
 
-104.865 GLU 205, TYR 547 
4 
 
-104.859 TYR 547, TYR 666 
5 
 
-103.891 - 
 
Among the compound reported in Table 1, compound 
Nos. 1, 2 and 3 show polar interactions with either 
GLU205 or GLU206. The interaction with either or both 
the amino acids may render the enzyme inactive towards 
GLP inhibitory activity. Therefore these compounds are 
expected to show DPP-IV inhibitory activity. Further 
compound 2 shows additional interactions with VAL 
207, ARG 358, TYR 547, TYR 662 and ASN 710 
indicating that the interactions with the active site will 
be more stable as compared to compounds 1 and 3. 
  
 
Figure 1: Binding mode of compound 2 (carbons: green, nitrogens: blue, oxygens: red, hydrogens: white) with the 
active site residues (yellow) of DPP-IV 
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CONCLUSION: 
DPP-IV inhibition is among the validated strategies for 
management of diabetes. In the past decade, DPP-IV 
inhibitors have found their use both as second line (with 
metformin) and first line treatments of T2DM. The 
present study focused on finding new scaffolds for DPP-
IV inhibition.  Among these, a benzimidazole 
derivative, compound 2 ((S)-2-(3-(2-(((3-
(hydroxymethyl)pyridin-2-yl)methyl)sulfinyl)-1H-
benzo[d]imidazol-6-yl)phenyl)acetic acid) was found to 
have polar interaction with GLU206, which is 
responsible for DPP-IV enzymatic activity, signifying 
its DPP-IV inhibitory potential. Furthermore, 
interactions with other active site residues imply 
probable stability of the complex. Thus this compound 
can prove to be a promising lead for the development of 
novel DPP-IV inhibitors. 
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